Clinical Trials Browser

Phase 2 × Active not recruiting × Gemcitabine × Clear all

NCT04940286 2026-04-16

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04481204 2026-04-15

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Phase 2 Active not recruiting

Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

NCT02101775 2026-04-13

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Active not recruiting

124 enrolled 17 charts

Brenner Tumor, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT02595892 2026-04-13

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Active not recruiting

70 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03609216 2026-04-13

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Phase 2 Active not recruiting

Infiltrating Bladder Urothelial Carcinoma

NCT04164082 2026-04-13

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT04310007 2026-04-13

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Lung Neoplasms

NCT05211323 2026-04-13

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

Phase 2 Active not recruiting

Gastrointestinal

Liver Neoplasms

NCT05632328 2026-04-08

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03093922 2026-04-07

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Phase 2 Active not recruiting

Carcinoma, Transitional Cell

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Phase 2 Active not recruiting

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT02436707 2026-03-27

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma

NCT04233866 2026-03-23

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04960618 2026-03-23

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

Phase 2 Active not recruiting

Mycosis Fungoides, Sezary Syndrome

NCT07480850 2026-03-18

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03816163 2026-03-12

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05502250 2026-03-06

HOVON164HL

Phase 2 Active not recruiting

Hodgkin Disease

NCT06449222 2026-02-25

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT05451290 2026-02-12

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

Phase 2 Active not recruiting

Gastrointestinal

Advanced Biliary Tract Carcinoma

NCT05908747 2026-02-10

Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06015659 2026-02-09

ZN-c3 + Gemcitabine in Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04999969 2026-02-03

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

Phase 2 Active not recruiting

126 enrolled 30 charts

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumours

NCT06027268 2026-02-03

ToPCourT

Phase 2 Active not recruiting

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07005336 2026-01-30

A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05500092 2026-01-28

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

NCT04630730 2026-01-21

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT05026905 2026-01-20

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05524168 2026-01-15

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT04539808 2026-01-14

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Phase 2 Active not recruiting

42 enrolled 13 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT03587662 2026-01-09

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT04241276 2026-01-07

STARPAC2

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Active not recruiting

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT02151084 2025-12-16

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

Phase 2 Active not recruiting

Gastrointestinal

Gallbladder Neoplasms, Recurrence

NCT04390399 2025-12-15

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05975307 2025-12-01

BCIRT-01

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT03137771 2025-11-25

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Phase 2 Active not recruiting

218 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT04386746 2025-11-17

GEMDOCE

Phase 2 Active not recruiting

27 enrolled 9 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

Phase 2 Active not recruiting

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

NCT05630183 2025-11-13

A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

NCT04216290 2025-11-12

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT01972919 2025-10-27

MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

23 enrolled 8 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02621151 2025-10-07

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

Phase 2 Active not recruiting

60 enrolled 11 charts

Muscle-invasive Urothelial Cancer of the Bladder

NCT00082706 2025-09-09

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

Phase 2 Active not recruiting

Urachal cancer, Urinary Bladder Neoplasms, Urethral Neoplasms

NCT04669197 2025-08-15

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer

Phase 2 Active not recruiting

Gastrointestinal

Untreated Resectable Pancreatic Adenocarcinoma

NCT06632951 2025-08-11

LIVIGNO-3

Phase 2 Active not recruiting

Carcinoma, Transitional Cell, Neoplasms

NCT02711553 2025-08-03

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Phase 2 Active not recruiting

309 enrolled 22 charts

Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT02755272 2025-07-04

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04594772 2025-07-02

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04098081 2025-07-01

1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT02632305 2025-06-26

AX-CSARC

Phase 2 Active not recruiting

Gastrointestinal

Unresectable Biliary Tract Cancer